Publicaciones (23) Publicaciones de Celia Fernández Rubio

2024

  1. Promising aryl selenoate derivatives as antileishmanial agents and their effects on gene expression

    Antimicrobial Agents and Chemotherapy, Vol. 68, Núm. 4

2023

  1. BRCT Domains: Structure, Functions, and Implications in Disease—New Therapeutic Targets for Innovative Drug Discovery against Infections

    Pharmaceutics, Vol. 15, Núm. 7

  2. Characterization of Leishmania Parasites Isolated from Naturally Infected Mammals

    Animals, Vol. 13, Núm. 13

  3. Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease

    Pathogens, Vol. 12, Núm. 7

2022

  1. Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis

    Pharmaceutics, Vol. 14, Núm. 11

  2. Selenium and protozoan parasitic infections: selenocompounds and selenoproteins potential

    Parasitology Research, Vol. 121, Núm. 1, pp. 49-62

  3. The BRCT Domain from the Homologue of the Oncogene PES1 in Leishmania major (LmjPES) Promotes Malignancy and Drug Resistance in Mammalian Cells

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

  4. Tratamientos, vacunas III:: Comunicaciones orales 11

    ParaJournal: Revista de la Sociedad Española de Parasitología, Núm. 1, pp. 163-171

2021

  1. Discovery and validation of lmj_04_brct domain, a novel therapeutic target: Identification of candidate drugs for leishmaniasis

    International Journal of Molecular Sciences, Vol. 22, Núm. 19

  2. In leishmania major, the homolog of the oncogene pes1 may play a critical role in parasite infectivity

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  3. Potential therapeutic targets shared between leishmaniasis and cancer

    Parasitology, Vol. 148, Núm. 6, pp. 655-671

2020

  1. Chitin binding protein as a possible RNA binding protein in Leishmania parasites

    Pathogens and Disease, Vol. 78, Núm. 1

  2. LmjF.22.0810 from leishmania major modulates the TH2-type immune response and is involved in leishmaniasis outcome

    Biomedicines, Vol. 8, Núm. 11, pp. 1-17

  3. Structural characterization by scattering and spectroscopic methods and biological evaluation of polymeric micelles of poloxamines and TPGS as nanocarriers for miltefosine delivery

    International Journal of Pharmaceutics, Vol. 578

2019

  1. Leishmanicidal activity of isoselenocyanate derivatives

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 2

  2. The novel serine/threonine protein kinase lmjf.22.0810 from Leishmania major may be involved in the resistance to drugs such as paromomycin

    Biomolecules, Vol. 9, Núm. 11

2018

  1. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions

    Journal of Dermatological Science, Vol. 92, Núm. 1, pp. 78-88

  2. Serological survey of cattle toxoplasmosis in Medea, Algeria

    Veterinary Parasitology: Regional Studies and Reports, Vol. 12, pp. 89-90

2017

  1. Construction of Two mCherry Plasmids (pXG-mCherry) for Transgenic Leishmania: Valuable Tools for Future Molecular Analysis

    Journal of Parasitology Research, Vol. 2017

2015

  1. Leishmanicidal activities of novel methylseleno-imidocarbamates

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 9, pp. 5705-5713